Reverse engineering of Perseris and development of compositionally equivalent formulations-Reference-Cited by-同舟云学术

Reverse engineering of Perseris and development of compositionally equivalent formulations

Published:2023-05 Issue: Volume:639 Page:122948
ISSN:0378-5173
Container-title:International Journal of Pharmaceutics
language:en
Short-container-title:International Journal of Pharmaceutics

Author:

Wang Xiaoyi,Bao Quanying,Wang Ruifeng,Wan Bo,Wang Yan,Qin Bin,Burgess Diane J.

Publisher

Elsevier BV

Subject

Pharmaceutical Science

Reference33 articles.

1. Budesonide loaded PLGA nanoparticles for targeting the inflamed intestinal mucosa-pharmaceutical characterization and fluorescence imaging;Ali;Pharm. Res.,2016

2. Atridox® Summary of Product Characteristics. Center for drug evaluation and research Approval package for Application number NDA 50-751, Food and Drug Administration, (2011).

3. Polymorphism of risperidone in supercritical fluid processes of micronization and encapsulation into aliphatic polyesters;Bagratashvili;Russ. J. Phys. Chem.,2017

4. Ultra-long-acting tunable biodegradable and removable controlled release implants for drug delivery;Benhabbour;Nat. Commun.,2019

5. Biodegradable poly(polyol sebacate) polymers;Bruggeman;Biomaterials,2008

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long acting injectables for the treatment of prostate cancer;Journal of Drug Delivery Science and Technology;2024-10

2. Towards in vitro – In vivo correlation models for in situ forming drug implants;Journal of Controlled Release;2024-08

3. In situ forming PLA and PLGA implants for the parenteral administration of Cannabidiol;International Journal of Pharmaceutics;2024-08

4. Bohemian Rhapsody of Future Drug Delivery Systems: Rational Changes Necessary for the Next Revolution;Molecular Pharmaceutics;2024-07-12

5. In-situ forming PLGA implants: Towards less toxic solvents;International Journal of Pharmaceutics;2024-05